Literature DB >> 17344041

The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.

Roman M Salasznyk1, Maria Zappala, Mingzhe Zheng, Lin Yu, Cynthia Wilkins-Port, Paula J McKeown-Longo.   

Abstract

Vitronectin is a plasma protein which can deposit into the extracellular matrix where it supports integrin and uPA dependent cell migration. In earlier studies, we have shown that the plasma protein, vitronectin, stimulates focal adhesion remodeling by recruiting urokinase-type plasminogen activator (uPA) to focal adhesion sites [Wilcox-Adelman, S. A., Wilkins-Port, C. E., McKeown-Longo, P. J., 2000. Localization of urokinase-type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors. Cell. Adhes. Commun.7, 477-490]. In the present study, we used a variety of vitronectin constructs to demonstrate that the localization of uPA to adhesion sites requires the binding of both vitronectin integrin receptors and the uPA receptor (uPAR) to vitronectin. A recombinant fragment of vitronectin containing the connecting sequence (VN(CS)) was able to support integrin-dependent adhesion, spreading and focal adhesion assembly by human microvessel endothelial cells. Cells adherent to this fragment were not able to localize uPA to focal adhesions. A second recombinant fragment containing both the amino-terminal SMB domain and the CS domain was able to restore the localization of uPA to adhesion sites. This fragment, which contains a uPAR binding site, also resulted in the localization of uPAR to adhesion sites. uPAR blocking antibodies as well as phospholipase C treatment of cells inhibited uPA localization to adhesion sites confirming a role for uPAR in this process. The SMB domain alone was unable to direct either uPAR or uPA to adhesion sites in the absence of the CS domain. Our results indicate that vitronectin-dependent localization of uPA to adhesion sites requires the sequential binding of vitronectin integrins and uPAR to vitronectin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344041     DOI: 10.1016/j.matbio.2007.01.009

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  7 in total

1.  Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.

Authors:  Henrik Gårdsvoll; Benedikte Jacobsen; Mette C Kriegbaum; Niels Behrendt; Lars Engelholm; Søren Østergaard; Michael Ploug
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

2.  A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Authors:  Degang Liu; Donghui Zhou; Bo Wang; William Eric Knabe; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

3.  Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling.

Authors:  Nicoleta L Popa; Jon E Wergedal; K-H William Lau; Subburaman Mohan; Charles H Rundle
Journal:  J Bone Miner Metab       Date:  2013-05-23       Impact factor: 2.626

4.  PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins.

Authors:  Daniel Vial; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2008-04-29       Impact factor: 5.285

5.  The amphioxus (Branchiostoma floridae) genome contains a highly diversified set of G protein-coupled receptors.

Authors:  Karl J V Nordström; Robert Fredriksson; Helgi B Schiöth
Journal:  BMC Evol Biol       Date:  2008-01-16       Impact factor: 3.260

Review 6.  Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.

Authors:  Michael Ploug
Journal:  Theranostics       Date:  2013-06-24       Impact factor: 11.556

Review 7.  Adipose-PAS interactions in the context of its localised bio-engineering potential (Review).

Authors:  Michal Nohawica; Abdelmounaim Errachid; Marzena Wyganowska-Swiatkowska
Journal:  Biomed Rep       Date:  2021-07-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.